Similarly, the GLORY-1 trial investigated the dual GLP-1/glucagon agonist mazdutide in adults with overweight or obesity, demonstrating significant weight loss and metabolic improvements [101]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.